Corrigendum to “The long-term safety and efficacy of vestronidase alfa, rhGUS enzyme replacement therapy, in subjects with mucopolysaccharidosis VII” [Mol Genet Metab 2020 Mar;129(3):219–227] (Molecular Genetics and Metabolism (2020) 129(3) (219–227), (S1096719219307851), (10.1016/j.ymgme.2020.01.003))

Raymond Y. Wang, José Francisco da Silva Franco, Jaime López-Valdez, Esmeralda Martins, Vernon Reid Sutton, Chester B. Whitley, Lin Zhang, Tricia Cimms, Deborah Marsden, Agnieszka Jurecka, Paul Harmatz

Research output: Contribution to journal › Comment/debate › peer-review

Fingerprint

Dive into the research topics of 'Corrigendum to “The long-term safety and efficacy of vestronidase alfa, rhGUS enzyme replacement therapy, in subjects with mucopolysaccharidosis VII” [Mol Genet Metab 2020 Mar;129(3):219–227] (Molecular Genetics and Metabolism (2020) 129(3) (219–227), (S1096719219307851), (10.1016/j.ymgme.2020.01.003))'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds